Congratulations to Kevin and Jamie on their 30th wedding anniversary. This milestone is not just a celebration of their enduring love and partnership but also a testament to their commitment to making a difference in the lives of others. In lieu of traditional gifts, Kevin and Jamie chose to channel their celebration into a cause…
Read More
You have the power to make a significant impact on the future of the APS Type 1 community by engaging with the networks of family, friends, employers, coworkers, and community members around you. Today, we are celebrating four stories that we hope will inspire you to harness the collective power of many. READ MORE
Read More
As many in our community return to school or start a new academic year, it is important for students and their families to be well-prepared. This is especially crucial for those transitioning into elementary school, middle or junior high, high school, or college. To support a smooth and successful school year for individuals with APS…
Read More
We are pleased to announce that Gaby Talarico has joined our board, adding another valuable patient voice to guide and inform our work. Now approaching 30 years old, Gaby was diagnosed with APS Type 1 at the age of 11 and was the first participant in the Natural History Study at the National Institutes of…
Read More
As Heather Talarico retires from our board of directors, the APS Type 1 Foundation extends its heartfelt gratitude to Heather for her dedicated service to our community over many years. As a co-founder of the Foundation, Heather has been a driving force behind our success. Her relentless efforts, including a decade of organizing the Driving…
Read More
Diabetes Center Director, UCSF, Mark Anderson MD PhD has been awarded the prestigious Coley Award from the Cancer Research Institute. The Coley Award honors groundbreaking contributions to cancer research, validating and highlighting the impact of innovative work, particularly in immunotherapy and recognizes Dr. Anderson’s foundational contributions to the understanding of immune tolerance mechanisms, self-antigen presentation,…
Read More
We are excited to announce the FDA’s approval of Yorvipath®, as the only FDA approved treatment for hypoparathyroidism in adults. YORVIPATH is a prodrug of parathyroid hormone (PTH[1-34]), administered once daily, designed to provide continuous exposure to released PTH over the 24-hour dosing period. Hypoparathyroidism is a rare endocrine disease caused by insufficient levels of…
Read MoreCongratulations are due to two of our graduating seniors: Sarah Brennan and Brooklyn Dwyer. Navigating the teen years and high school is hard enough without the added challenge of a rare disease. These two young women inspire us all to never give up and reach our dreams. We wish you both the very best in…
Read More
Congratulations to our medical advisory committee members, Drs. Michail Lionakis and Maureen Su, on their recent publications in the prestigious New England Journal of Medicine, entitled The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1 and JAK Inhibition Immunotherapy for APS-1, respectively. In his article, Dr. Lionakis, whose work led to the first-ever clinical trial for APS Type…
Read MoreWe are excited to share that Kayla Mills, one of our young adults with APS Type 1, was crowned Miss Arc Broward on May 19, 2024. The Miss Arc Broward Pageant empowers girls and teens with disabilities to pursue their dreams. Kayla is literally using her voice to advocate for others like her with “hidden”…
Read More
The APS Type 1 Foundation, with generous sponsorship by the Clinical Immunology Society and the National Institute of Allergy and Infectious Disease, hosted a FOCIS (Federation of Clinical Immunology Societies) Member Society Symposium at the FOCIS 2024 Annual Meeting in San Francisco on June 18th. Over 120 clinicians and scientists attended. The speakers delivered incredible talks about cutting-edge research relating to APS…
Read More
